Merck & Company (MRK) - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US58933Y1055

Merck & Co., Inc. is a global healthcare company that operates internationally. Its operations are divided into two main segments: Pharmaceutical and Animal Health. The Pharmaceutical segment focuses on providing a wide range of products for human health, including oncology, acute care, immunology, neuroscience, virology, cardiovascular, and diabetes treatments, along with vaccines for pediatric, adolescent, and adult patients.

The Animal Health segment of Merck & Co., Inc. specializes in the discovery, development, and distribution of veterinary pharmaceuticals, vaccines, and health management solutions. They also offer digitally connected identification, traceability, and monitoring products for animals. The company's clientele includes drug wholesalers, retailers, hospitals, government agencies, managed healthcare providers like HMOs and pharmacy benefit managers, as well as physicians, veterinarians, and animal producers.

Merck & Co., Inc. has formed strategic partnerships with various organizations such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics LP, and Gilead Sciences, Inc. to collaborate on the development and commercialization of long-acting HIV treatments. Additionally, they have collaborations with other companies like Bionomics, Ankyra Therapeutics, Phanes Therapeutics, and Daiichi Sankyo Company, Limited for innovative treatment solutions in different medical areas.

Founded in 1891, Merck & Co., Inc. is headquartered in Rahway, New Jersey. For more information, visit their website at

AI improved, may contain errors or wrong assumptions

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Merck & Company (MRK) - Stock Price & Dividends

MRK Stock Overview

Market Cap in USD 317,842m
Sector Healthcare
Industry Drug Manufacturers - General
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception 1978-01-13

MRK Stock Ratings

Fundamental 2.58
Dividend 7.63
Growth 5y 6.67
Rel. Performance vs Sector 0.50
Analysts 4.29
Fair Price Total Ret. 126.87
Fair Price DCF 106.93

MRK Dividends

Yield 12m 2.29%
Yield on Cost 5y 4.43%
Dividends CAGR 5y 6.55%
Payout Consistency 97.8%

MRK Growth Ratios

Growth 12m 23.56%
Growth Correlation 12m 3%
Growth Correlation 3m 91%
CAGR 5y 13.96%
CAGR / Mean Drawdown 1.90
Sharpe Ratio 12m 1.01
Alpha vs SP500 12m 7.03
Beta vs SP500 5y weekly 0.45
CAPM 6.47%
Average Daily Range 2m 1.39%
Regime Oscillator 70.04
Volatility GJR Garch 1y 18.64%
Price / SMA 50 7.22%
Price / SMA 200 17.27%
Current Volume 5697.2k
Average Volume 20d 6901.9k

External Links for MRK Stock

Wall Street JournalBenzingaYahoo Finance
X (Twitter)Stocktwits
Fund Manager Positions
What is the price of MRK stocks?
As of February 29, 2024, the stock is trading at USD 128.19 with a total of 5,697,212 shares traded.
Over the past week, the price has changed by +0.05%, over one month by +5.70%, over three months by +28.89% and over the past year by +20.50%.
Why is MRK stock down?
Check with which Index or Commodity MRK has the highest Correlation, do they have a common driver?
Review the Fundamentals to find weaknesses (Debt, low returns). Check the Performance of the Peer-Group to find out, if the entire sector is under pressure.
Period Return MRK Return S&P 500
1 Month 5.70% 3.05%
3 Months 28.89% 11.73%
12 Months 20.50% 29.22%
What is the forecast for MRK stock price target?
According to ValueRays Forecast Model, MRK Merck & Company will be worth about 138.8 in February 2025. The stock is currently trading at 128.19. This means that the stock has a potential upside of +8.28%.
Issuer Forecast Upside
Wallstreet Target Price 133.8 4.4%
Analysts Target Price 117.2 -8.6%
ValueRay Target Price 138.8 8.3%

The Journey of Merck & Company Inc: From Humble Beginnings to Global Pharma Leader

History of Merck & Company Inc

Founded in 1891 by George Merck in the United States, Merck & Company Inc, known outside the U.S. and Canada as MSD, has a storied history that spans more than a century. Originating from a small chemical company, it has evolved into one of the world's leading pharmaceutical and healthcare giants. The journey of Merck is marked by its dedication to research and development (R&D), leading to breakthroughs in medicines and vaccines across a broad range of diseases.

Core Business

At the heart of Merck & Company Inc's operations is its commitment to improving health worldwide. The core business focuses on pharmaceutical products, including a wide array of prescription medicines and vaccines. Merck is renowned for its contributions to oncology, infectious diseases, cardiology, and diabetes among others. With a robust R&D department, Merck continuously works on developing new treatments and therapies to address unmet medical needs.

Side Businesses

Besides its primary pharmaceutical ventures, Merck & Company Inc has diversified its business into other areas, enhancing its portfolio and market reach. This includes animal health products, which offer a range of veterinary medicines and vaccines. The company also engages in the development and promotion of biopharmaceutical solutions through strategic collaborations and acquisitions, thus supporting various healthcare needs beyond human medications.

Current Market Status

As of the latest reports, Merck & Company Inc remains a formidable player in the pharmaceutical industry with a strong global presence. It continues to experience growth, thanks in part to its innovative product pipeline and strategic market initiatives. The company has been resilient in navigating challenges, including competitive pressures and global health crises, by leveraging its R&D strengths and adapting to changing market dynamics. Merck's commitment to health care innovation and its ability to address the needs of patients and healthcare providers worldwide solidify its status as a leading pharmaceutical company.